| From: Moonray | 6/1/2021 9:07:44 PM | | | | | | EXCLUSIVE U.S. opens criminal probe into alleged lapses at Eli Lilly plant
The U.S. Justice Department has launched a criminal investigation into Eli Lilly and Co (LLY.N)focused on alleged manufacturing irregularities and records tampering at a factory in Branchburg, New Jersey, that produces the pharmaceutical giant’s COVID-19 therapy and other drugs, three people familiar with the matter said.
The probe represents a significant escalation of the government scrutiny on Lilly. The pharmaceutical company, one of the world's largest, has been under examination for more than a year by the U.S. Food and Drug Administration over alleged manufacturing and records violations at the Branchburg factory.
Reuters questioned Lilly about the criminal inquiry on Wednesday. On Thursday morning, the company disclosed in a securities filing that it had received a subpoena from the Justice Department in May seeking documents related to the Branchburg factory.
The company did not disclose anything more about the nature or focus of the investigation and said it was cooperating fully in the matter.
More at: reuters.com
o~~~ O |
| | Eli Lilly | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Moonray | 6/1/2021 9:20:34 PM | | | | | | Eli Lilly gets Indian emergency use nod for Covid-19 antibody drug combination
The company said it is in talks with the Indian government and regulatory authorities to donate the drugs to help speed up access and provide more treatment options for Covid-19
Eli Lilly and Co's antibody drug combination has received an emergency use approval in India for the treatment of mild-to-moderate Covid-19, bolstering the country's arsenal of medicines to tackle a devastating second wave of the pandemic.
A combination of the U.S. drugmaker's monoclonal antibodies bamlanivimab and etesevimab has been given approval for restricted use in emergency situations in hospital settings in adults, the company's Indian unit said in an emailed statement.
More at: kathmandupost.com
o~~~ O |
| | Eli Lilly | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Moonray | 6/1/2021 9:27:56 PM | | | | | | Distribution of Eli Lilly COVID-19 therapy
paused in 8 states over variant concerns
For now, the FDA recommends using
Regeneron's antibody cocktail instead.
Federal health authorities have paused distribution
of Eli Lilly's monoclonal antibody cocktail in eight
tates over COVID-19 variant efficacy concerns.
The COVID-19 treatment will halt distribution in
Arizona,
alifornia,
Florida,
llinois,
Indiana,
Massachusetts,
Oregon and
Washington
"until further notice" due to variants' elevation in those
states, the U.S. Department of Health and Human
Services and Assistant Secretary for Preparedness
and Response announced in a bulletin this week.
More at: abcnews.go.com
o~~~ O |
| | Eli Lilly | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: Moonray who wrote (623) | 12/17/2021 11:51:41 AM | | From: Lance Bredvold | | | | I have a 270 call sold for January and during the pop this week sold another at $280 for July. While the news has been good and I have actually penciled in EPS of $8.20 (above the $7.95 speculated 2 posts ago) that puts my $270 call at a PE of nearly 33. That's more than the company has shown as a high for any of the last 10 years except 2021. Clearly $280 is just as pricy so I'm feeling pretty secure in my sales which were both for $22.00. Of course I could be wrong, but I think the odds are excellent that I'll profit from these sales.
If I had some of my shares in retirement accounts I'd probably sell as it bounced so high the other day, but I don't want to claim the huge gain on the shares in my taxable accounts at this time, so a nice 8% bonus is welcome though it also entails some tax expense. |
| | Eli Lilly | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Lance Bredvold who wrote (624) | 4/8/2022 9:15:38 PM | | From: Lance Bredvold | | | | | I don't know about anyone else, but I just don't believe prices and PE's just keep going up forever. The Jan 270 expired nicely but the July 280 is far underwater and an additional Oct 300 is also looking pretty dumb at the moment. Yet getting over $20 for each one feels pretty good for a while at least and I think I'll have the courage to sell a $320 whenever I can get $25 or so for them. |
| | Eli Lilly | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| |
